日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

The efficacy and safety of gemcitabine and docetaxel in pseudomyogenic hemangioendothelioma: a multi-center experience

吉西他滨联合多西他赛治疗假性肌源性血管内皮瘤的疗效和安全性：一项多中心研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-14376-6
Cai, Qiyan; Xu, Bushu; Zhang, Peng; Ma, Jie; Liang, Jiahui; Le, Liyuan; Li, Shining; Yang, Jing; Pan, Qiuzhong; Peng, Ruiqing; Zhang, Xing
心血管
发表日期：2025
文献求助 收藏

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial

安罗替尼作为一线化疗后晚期软组织肉瘤的维持治疗（ALTER-S006）：一项多中心、开放标签、单臂 II 期试验

期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2023.102240
Xu, Bushu; Pan, Qiuzhong; Pan, Hua; Li, Haomiao; Li, Xianan; Chen, Jing; Pang, Danmei; Zhang, Baoqing; Weng, Desheng; Peng, Ruiqing; Fang, Meiyu; Zhang, Xing
发表日期：2023
文献求助 收藏

P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis

P4HA2诱导的脯氨酰羟基化抑制YAP1介导的前列腺癌细胞迁移、侵袭和转移

期刊:Oncogene
影响因子:7.3
doi:10.1038/s41388-021-02000-3
Zhu, Ming; Peng, Ruiqing; Liang, Xin; Lan, Zhengdao; Tang, Ming; Hou, Pingping; Song, Jian H; Mak, Celia Sze Ling; Park, Jiwon; Zheng, Shui-Er; Huang, Ailing; Ma, Xingdi; Chen, Ruidong; Chang, Qing; Logothetis, Christopher J; Jain, Abhinav K; Lin, Sue-Hwa; Katayama, Hiroyuki; Hanash, Samir; Wang, Guocan
YAP1
肿瘤
肿瘤免疫
YAP
细胞生物学
前列腺癌
发表日期：2021
文献求助 收藏

The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study.

阿昔替尼联合帕博利珠单抗激活的自体DC-CIK细胞免疫疗法治疗晚期肾细胞癌患者的疗效和安全性：一项2期研究

期刊:Clinical & Translational Immunology
影响因子:3.8
doi:10.1002/cti2.1257
Song Meng-Jia, Pan Qiu-Zhong, Ding Ya, Zeng Jianxiong, Dong Pei, Zhao Jing-Jing, Tang Yan, Li Jingjing, Zhang Zhiling, He Junyi, Yang Jieying, Huang Yue, Peng Ruiqing, Wang Qi-Jing, Gu Jia-Mei, He Jia, Li Yong-Qiang, Chen Shi-Ping, Huang Rongxing, Zhou Zi-Qi, Yang Chaopin, Han Yulong, Chen Hao, Liu Heping, Xia Shangzhou, Wan Yang, Weng De-Sheng, Xia Liming, Zhou Fang-Jian, Xia Jian-Chuan
细胞生物学
肿瘤免疫
发表日期：2021
文献求助 收藏

Comparison of the MAID (AI) and CAV/IE regimens with the predictive value of cyclic AMP-responsive element-binding protein 3 like protein 1 (CREB3L1) in palliative chemotherapy for advanced soft-tissue sarcoma patients.

比较 MAID (AI) 和 CAV/IE 方案与环磷酸腺苷反应元件结合蛋白 3 样蛋白 1 (CREB3L1) 在晚期软组织肉瘤患者姑息化疗中的预测价值

期刊:Journal of Cancer
影响因子:3.2
doi:10.7150/jca.28734
Xiao Wei, Liang Yao, Que Yi, Li Jingjing, Peng Ruiqing, Xu Bushu, Wen Xizhi, Zhao Jingjing, Guan Yuanxiang, Zhang Xing
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏

A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure

伊马替尼治疗失败后，舒尼替尼治疗晚期隆突性皮肤纤维肉瘤取得了良好的疗效。

期刊:Oncotargets and Therapy
影响因子:2.8
doi:10.2147/OTT.S150235
Xiao, Wei; Que, Yi; Peng, Ruiqing; Ding, Ya; Zhao, Jingjing; Wen, Xizhi; Weng, Desheng; Zhang, Xiaoshi; Guan, Yuanxiang; Zhang, Xing
发表日期：2018
文献求助 收藏

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis

帕唑帕尼、索拉非尼和舒尼替尼治疗晚期软组织肉瘤患者的治疗相关不良反应：一项汇总分析

期刊:Cancer Management and Research
影响因子:2.6
doi:10.2147/CMAR.S164535
Que, Yi; Liang, Yao; Zhao, Jingjing; Ding, Ya; Peng, Ruiqing; Guan, Yuanxiang; Zhang, Xing
发表日期：2018
文献求助 收藏

The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series

中国转移性黑色素瘤患者应用免疫检查点抑制剂的经验：一项回顾性病例系列研究

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-017-1989-8
Wen, Xizhi; Ding, Ya; Li, Jingjing; Zhao, Jingjing; Peng, Ruiqing; Li, Dandan; Zhu, Baoyan; Wang, Yao; Zhang, Xing; Zhang, Xiaoshi
黑色素瘤
免疫/内分泌
发表日期：2017
文献求助 收藏